ÂÜÀòÂÒÂ×

Patrice Allibert, PhD, currently serves as the President and Chief Executive Officer of OxyNov, a medical device company in Québec City, specializing in the FreeO2 oxygen delivery monitoring apparatus, especially critical during the Covid-19 pandemic. In addition, Patrice Allibert holds several influential roles, including member of the Board of Directors for RNA Disease Diagnostics and Québec International, and task force member for the Canadian Antimicrobial Innovation Coalition. Experience includes presidency at MDx Consulting and board membership at Immunexpress, which focuses on sepsis diagnostics. Previously, Patrice Allibert was the CEO of GenePOC, successfully leading the company's sale for 160 million CAD, and held significant positions at FOLIA BioTech, the Canadian Institute of Health Research, and BD, where key innovations in molecular diagnostics were developed. Patrice Allibert obtained a Doctor of Philosophy in Molecular Biology from Université Joseph Fourier (Grenoble I) between 1982 and 1986.